Hemophilia is a very simple disease in that it results from a deficiency in a single clotting factor and so gives rise to excessive bleeding from minimal trauma. There is no vascular defect, no associated circulatory lesion and if this missing factor, anti-hemophiliac globulin (AHG) or Factor VIII, can be given in sufficient quantity, the bleeding ceases and the disease is then cured, albeit temporarily. Nevertheless, himophilia remains a very complex disease because bleeding can occur in any one site or in multiple sites and can produce a vast number of varying effects. This paper emphasizes bleeding into a joint space because (1) it is the commonest site of bleeding in both children and adults; (2) if untreated or if treated incorrectly, the resulting deformities can lead to a lifetime of misery for the patient; (3) new methods of preparing AHG have to some extent revolutionized the treatment of hemophilia and especially of hkmarthrosis and muscle bleeds.
In child or adult, pain is the predominating feature, usually due to distension of the joint capsule, though it may occur with much smaller bleeds. Swelling, with immobility, is the chief sign. The pain is excruciating, when any movement, especially rotation, is attempted; lessening severity of the pain (allowing for the influence of any analgesic drug) is one indication that bleeding into the joint has stopped.
The joints most commonly affected are knee, elbow, and ankle, in that order. A patient may have one particular joint more frequently affected than the others; the older patient is often aware of this and able to forecast a bleed into the joint, and this helps to plan early treatment.
Most hiemophiliacs are now registered with one or other of the special centres in this country: all are diagnostic centres under the direction of a hematologist who has a special interest in coagulation defects, all try or should try to be treatment centres as well. This means a close collaboration between the hmematologist and his clinical colleagues, physician, surgeon, orthopaedic surgeon and dentist.
In dealing with joint bleeds, the importance of early admission to hospital should be discussed with the parents or with the patient himself if sufficiently adult and with the general practitioner, with whom a close liaison is maintained. With children it should always be regarded as an emergency. The parents must be encouraged to bring the child to hospital immediately and the haematologist in charge of the centre must be prepared to deal with such emergencies. There is no doubt that when sufficient AHG is given to a hlmophiliac child with an acute hlmarthrosis, the bleeding ceases, the pain goes and movement can be restored very quickly. The relief of pain can be quite dramatic once sufficient AHG is given and this form of treatment is far superior to any analgesics. If analgesics are given, usually in addition to the AHG, then the safest drugs are the paracetamol group, codeine and DF 118.
The question of aspiration is a difficult one. The presence of blood in the joint cavity, apart from the overdistension of the capsule, is harmful: it causes marked vasodilatation of the capsular and epiphyseal bone vessels and so repeated bleeding and it may even be responsible for the disintegration of joint cartilages (Lack 1959) . Once AHG has been given in sufficient quantity, aspiration would seem to be of little use; the blood in the cavity clots and only with a very wide bore needle can anything be removed. Aspiration, once decided upon, must be timed by consultation between the himatologist and orthopedic surgeon and is best carried out at the beginning of AHG therapy so that the bleeding will cease at the same time as the optimum amount of effusion has been withdrawn from the joint. Treatment is therefore aimed at replacing the missing clotting Factor VIII and this means adequate stocks of active preparations. Factor VIII cannot be prepared synthetically and is only available in plasma which, if human in origin, must be fresh or fresh frozen. Factor VIII is extremely labile and great care must be taken to ensure that the end product is sufficiently active to be of therapeutic value. Fresh frozen plasma is normally made available by Regional Blood Transfusion Centres.
Some centres use pools of plasma from a number (8-10) of group A males. This produces a higher concentration of Factor VIII than from a general pool: it has been established by many workers and most recently by Preston and Barr (1964) that group A blood has'an 8% higher AHG level than group 0 blood, males 6-5% higher than females. This plasma can be used for either 0 or A recipients. Some centres prefer to use group AB plasma only and this limits the availability of donors. Moreover, the risk of 10 homologous serum jaundice is enhanced by using a large pool like this.
If fresh.frozen plasma is used to raise the AHG level, it has to be given by drip transfusion. Veins are very precious to hmmophiliacs: 'cut downs' must be avoided and used only as a last resort; great patience is needed in transfusing a small male child, almost invariably plump from lack of exercise and also invariably with a total absence of accessible veins.
Apart from fresh frozen plasma, AHG is available from the Blood Products Laboratory at the Lister Institute, but the distribution is strictly limited. Animal AHG prepared from cattle, pigs or sheep can be purchased commercially and is best used for major surgery as it is not in short supply. For a course of treatment to cover a major operation, about 75 to 80 ampoules, each equivalent to 800 ml human plasma are used. There are snags with using animal AHG. First, it is antigenic; although recent reports suggest that it is possible to give more than one course of the same animal preparation, it is probably wisest to avoid this and, if a second course is subsequently needed, to use a different animal preparation or to use human AHG. Secondlydificulties are sometimes experienced in getting animal AHG into solution, especially without frothing. Thirdly, anaphylactic and pyrogenic reactions can occur which can be alarming.
None of these preparations, animal or human AHG concentrate, is usually advocated for the treatment of a hamarthrosis and in the past fresh frozen plasma has been used. More recently a new advance has paved the way for yet another preparation of Factor VIII which has many definite advantages. This is the cryoprecipitate first described by Judith Pool of the Coagulation Department of Stamford University (Pool et al. 1964) . In 1959 she first reported that the cold-insoluble precipitate which forms when frozen plasma is thawed in the cold is rich in AHG. At that time it was not realised how, rich this product was but now it has been conclusively-demonstrated that these cold precipitates contain over 70% of the total plasma AHG.
A very simple method of preparing this material has now been developed, demanding only a refrigerated centrifuge and plastic double containers. Donors are bled into the larger of the two plastic bags, the primary bag, in standard acid citrate dextrose solution and the blood mixed thoroughly during the collection. The primary bag is then centrifuged in a pre-cooled, refrigerated centrifuge at 4°C. This packs the red cells and the supernatant plasma is then expressed into the attached transfer bag. It flows easily and with little or no contamination by red cells. After clamping, the plasma in the secondary bag is deep frozen in a dry-ice alcohol mixture until it is frozen solid. Meanwhile, the red cells in the primary bag are kept on wet-ice for protection. Once the plasma is frozen solid, it and the primary bag are placed in a standard 4°C refrigerator for cold thawing. This takes about twenty-four hours. The supernatant plasma which has thawed is then drained back into the primary bag. The two bags are sealed and separated. There is now the AHGrich, frozen 'sludge' in one bag, and in the other an ordinary plastic pack of whole blood minus most of its Factor VIII. This 'sludge', when required for use, is easily thawed and dissolved, either in saline or a little residual plasma; it can then be taken into a 20 ml syringe and given by simple intravenous injection, which can be repeated as often as required.
There are the following advantages: no intravenous drip need be set up; there is little risk of hepatitis; the correct ABO group can be used but, as the number of red blood cells carried over is minimal, this is not of importance; there is no wastage of blood, the AHG concentrate is merely a by-product of the blood and can be stock-piled for future use.
In conclusion, therefore, hmmarthroses are best treated by immediate plasma infusion with or without aspiration of the joint, with every chance that the incapacity to the joint can be resolved in a matter of days. The statutory procedure for dealing with the resettlement of disabled patients is by referral to the Disablement Resettlement Officer (DRO) of the Ministry of Labour. This involves the completion of a medical form DPl which must include a statement that the patient will have a residual disability for twelve months. It generally follows that any action concerning resettlement will not be put in hand until the patient's treatment is completed.
